The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
about
RANK-RANKL signalling in cancerBisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidenceMicro-RNAs, New performers in multiple myeloma bone marrow microenvironmentNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewThree-Dimensional Microfluidic Tri-Culture Model of the Bone Marrow Microenvironment for Study of Acute Lymphoblastic LeukemiaExosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction moleculesReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersSpatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapyBCL6 modulation of acute lymphoblastic leukemia response to chemotherapyMolecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma.Tumors as organs: complex tissues that interface with the entire organismRole of malignant ascites on human mesothelial cells and their gene expression profilesGrowth of tyrosine kinase inhibitor-resistant Philadelphia-positive acute lymphoblastic leukemia: Role of bone marrow stromal cellsImmunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.Microenvironmental regulation of therapeutic response in cancerIL-6 and MYC collaborate in plasma cell tumor formation in mice.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Game theory in the death galaxy: interaction of cancer and stromal cells in tumour microenvironment.Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid LeukaemiaConductive interstitial thermal therapy (CITT) inhibits recurrence and metastasis in rabbit VX2 carcinoma model.Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Tumorigenic and adhesive properties of heparanase.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Differential adhesive properties of sequestered asexual and sexual stages of Plasmodium falciparum on human endothelial cells are tissue independentTargeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.Prevention of bone metastases and management of bone health in early breast cancer.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionIntegrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1.Contribution of bone microenvironment to leukemogenesis and leukemia progression.The intricate role of CXCR4 in cancer.Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients
P2860
Q26747442-7FC496BE-B221-49C4-B419-854E15E16C74Q26795493-CC4F94CF-D7F8-4FB6-B14C-CF8ACA0D3256Q26823660-40110789-F525-4938-A918-4AB754C46B9FQ27304386-1506D72B-1309-4668-9DF1-A3FD0DC6C0BFQ27313269-146EE17F-7B10-478F-ABFD-A69FC47269E1Q27333594-7B1E1932-861F-49BD-B485-6D7146FA419FQ28082793-787B3746-15F0-4D2A-AAA5-7A3D9DCA2B48Q28544732-D01E9975-6DA3-4F37-A7FD-ACD5720E70C2Q28829626-55A481CD-486A-4343-9C27-CBA528DE9EE3Q30444038-6813EB00-ECD6-41B3-B1F4-95B8C5C85C12Q30495528-B96FE860-9FD7-4346-B3CE-7EDFA3BA698FQ33559857-EE29A807-F3DC-4DC4-9FD3-744E6B9F06C0Q33597756-516D9304-8135-44F2-B1FA-44D62B296A3CQ33597774-019A0D43-614F-46A4-AE43-5F8443DB2355Q33607950-D511D143-68E6-4218-B02A-48010723C739Q33636086-45799737-A279-4F24-82EF-DDC1227D16ABQ33654609-5F87C321-3302-47BE-81FE-1E1D624335EBQ33706389-3D7D272A-72EB-4C21-AEA1-CC41174B2027Q33775647-952B0CAD-8995-41E5-99A8-9798EB6BC7F2Q33808741-2590758B-88DD-4BDA-8650-C787740E74FCQ33852603-BA3FA8A1-2426-4966-AF9C-F084AF6EF357Q33914050-4D753B2A-506E-48F8-9B35-3BA9B7D7ED28Q33965681-298BB4FA-3C59-4092-BDC4-CAB0191C6302Q34012393-F52744A1-4A13-4FC9-B4E5-66AAE4CF05E1Q34026194-19535F4A-2ED3-416F-A774-3378F6B69798Q34106863-52D17EB0-B50B-4C39-83CD-313A4A57AC31Q34137792-E7E9B442-A9DD-464A-AD67-F9650CA528C4Q34145863-E37328EA-4FAC-48EB-86CB-508B20C138B6Q34171103-0CE7AF39-25A1-45F2-8178-21DA2B192A6AQ34173253-4BBCBC79-8218-4460-BAA3-4CD38E956EEEQ34184717-79BF365E-7EF8-45E2-9DED-37358B839368Q34195072-E1D5F194-1E55-4380-997B-144FDB27BA87Q34199935-8CB51F54-F87A-49F4-81CC-841F516A9515Q34292287-D2EFB5D8-81F5-412D-BD47-43400A070F5BQ34613485-92BCE131-2961-4849-83C5-0BC5B3C6ABF7Q34649120-4C6C56C7-1F34-4D32-8C8C-04B07791718CQ34781192-6C5D09DD-3063-4774-B4DE-9EFA001D7EEFQ35037058-0356A301-5F4F-4539-BBCC-E4DD2983090CQ35067624-26E7308A-DFAF-4AA2-A899-2163B9659ED4Q35095543-8D4679BB-1AF6-452A-AC9E-175A214C0863
P2860
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@en
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@nl
type
label
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@en
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@nl
prefLabel
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@en
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@nl
P2093
P1476
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.
@en
P2093
Lori A Hazlehurst
Mark B Meads
William S Dalton
P304
P356
10.1158/1078-0432.CCR-07-2223
P407
P577
2008-05-01T00:00:00Z